AI-enabled drug discovery that predictably unlocks hard to drug targets to transform chronic disease.
About Montai
Montai is a different kind of drug company, purpose-built to make big leaps forward in the predictable discovery of great drugs for chronic diseases.
Montai is pioneering at the intersection of machine learning, biology, and diverse untapped chemistry that is rich with potential solutions to disease — Anthromolecule™ compounds. Tested and refined through eons of human co-evolution through chronic consumption, the topologically rich structures across Anthromolecules offer opportunities to engage complex biological targets with precision and selectivity, making this diverse chemistry a privileged starting point for small molecule drugs.
Our Mission
Many of today's innovative therapies remain out of reach or insufficient for most patients. What's more, finding new oral medicines historically has been largely a trial-and-error endeavor with many of the most important validated biological pathways considered undruggable with small molecules. This is particularly true for inflammation and immune system disorders. Montai aims to change this.
-
169M
Adults living with
inflammatory & immune diseases -
2/3
Advanced therapies are injectable biologics -
97%
Of patients Lack access to advanced therapies -
70-90%
Prefer oral medicines over injectables
The CONECTA Platform
Diverse, Untapped Bioactive Chemical Space at Unprecedented Scale
Montai is aggregating and curating the world's largest, fully-annotated set of Anthromolecules - bioactive molecules humans have chronically consumed.
We have developed proprietary tools to generate and curate over 1 billion synthetically accessible analogs with good drug-like properties derived from Anthromolecules. This opens accessibility to this privileged diverse chemical space at scale for efficient drug development.
Embedded in this space are many proven molecular modalities for unlocking complex biology, such as covalent binders, allosteric inhibitors, molecular glues and protein-protein interaction inhibitors. Now we can search this space universally for the first time to find optimal solutions for complex biology.
Precision Pathway Connections to Target Biology
Powered by next-generation multimodal foundation models trained on billions of curated and proprietary data points, Montai's AI tools efficiently unlock precision connections between the diverse Anthromolecule chemical space and the known drivers of complex disease biology governing inflammation and immune diseases, creating new opportunities for pill-based medicines.
Integrated Decisioning
CONECTA supercharges drug discovery and development with incredible efficiency, insights, and capabilities. More and earlier integrative decision making across multiple differentiated candidates, plus candidate discovery from diverse chemotypes de-risks development and provides unprecedented optionality.
What would have taken 1,000 years of experimentation can be done in a day.
Our Platform Visualized
Montai has built the world's leading AI to decode the language of Anthromolecule chemistry to predictably unearth and optimize nature's bioactive solutions.
See how we do it.
The CONECTA® pipeline
| Target | Discovery |
Lead Optimization Lead Op. |
IND Enabling |
Phase 1 |
|---|---|---|---|---|
|
NRF2 (MTAI-1025) Ulcerative Colitis |
★ FIH 2026 | |||
| Transcription Factor |
||||
| Biologics Replacement |
||||
Oncology
|
-
1B+
Superior starting points for drug discovery -
12
Pathways validated in CONECTA® platform -
4
hard-to-drug targets drugged with new mechanisms
We envision a world where, instead of regular and costly infusions, a convenient and safe pill for long-term use effectively treats a chronic disease, where solutions exist for diseases that today have none.
Featured News
-
Montai Therapeutics Presents Preclinical Data on NRF2 Agonist in Ulcerative Colitis at ACAAI Annual Meeting
-
Montai Therapeutics Appoints Hans Hull as Chief Operations Officer
-
Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer
-
Spotlight: Montai Builds a Multimodal AI Platform for Drug Discovery Using NVIDIA NIM Microservices
-
Montai Therapeutics Appoints Renowned Chemical Innovator Larry Hamann to Company's Board of Directors, Convenes Multidisciplinary Scientific Advisory Board to Inform Strategic Momentum
-
How 3 Mass. companies are using AI to design drugs
-
Breaking Boundaries in Chemical Combinatorics Machine Learning: Unveiling the ComboPath Model at NeurIPS 2023
-
Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company's First Chief Medical Officer
-
Montai Health Adds Industry Leaders to its Board of Directors
-
Flagship Pioneering Unveils Montai Health to Treat and Preempt Chronic Disease Afflicting Two Billion People Worldwide
Join Us
Contact Us
-
Partnerships
We welcome the opportunity to partner with experts across areas who share our passion for creating Anthromolecule™ medicines and want to collaborate to accelerate the development of safe, efficacious and accessible therapies across diseases.
partnerships@montai.com -
Press
For media inquiries or the latest on research, thought leadership, company news, and events contact:
press@montai.com